Improved analysis of 5-fluorouracil and 5,6-dihydro-5-fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling

Therapeutic Drug Monitoring

Volumn 27, Issue 3, 2005, Pages 362-368

  Di Paolo, Antonello ^a,d   Danesi, Romano ^a   Ciofi, Laura ^a   Vannozzi, Francesca ^a   Bocci, Guido ^a   Lastella, Marianna ^a   Amatori, Federica ^a   Martelloni, Bianca Maria ^a   Ibrahim, Toni ^b   Amadori, Dino ^b   Falcone, Alfredo ^c   Del Tacca, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

^b L Pierantoni Hospital   (Italy)

^c Division of Medical Oncology   (Italy)

^d Transplants and Advanced Technologies in Medicine   (Italy)

Author keywords

5 fluorouracil; Dihydropyrimidine dehydrogenase; Diode array detector; Pharmacokinetics; Therapeutic drug monitoring; Toxicity

Indexed keywords

ACETIC ACID; DIHYDROFLUOROURACIL; DIHYDROPYRIMIDINE DEHYDROGENASE; ETHER; FLUOROURACIL; FOLINIC ACID; POTASSIUM DIHYDROGEN PHOSPHATE; PROPANOL; SODIUM SULFATE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COEFFICIENT OF LINEARITY; COEFFICIENT OF VARIATION; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DIODE ARRAY DETECTION; DRUG ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG ISOLATION; DRUG MONITORING; ELUTION; ENZYME ACTIVITY; ENZYME DEFICIENCY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH RISK PATIENT; HUMAN; HUMAN CELL; LIMIT OF DETECTION; LIMIT OF QUANTIFICATION; LINEAR SYSTEM; MALE; MAXIMUM PLASMA CONCENTRATION; PARAMETER; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACOKINETICS; PRIORITY JOURNAL; PRODUCT RECOVERY; QUANTITATIVE ANALYSIS; SIGNAL DETECTION; STOMATITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; VARIANCE;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG MONITORING; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; URACIL;

EID: 20044380148     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000162016.11148.1b     Document Type: Article

References (28)

1. Chu E, Mota AC, Fogarasi MC. Antimetabolites. In: De Vita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principle and Practice of Oncology. Philadelphia: Lippincott Williams & Wilkins, 2003, pp 388-414.
2. Di Paolo A, Ibrahim T, Danesi R, et al. Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients. Ther Drug Monit. 2002;24:588-593.
3. Di Paolo A, Danesi R, Falcone A, et al. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol. 2001;12:1301-1306.
4. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989;16:215-237.
5. Milano G, Etienne MC, Pierrefite V, et al. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer. 1999;79:627-630.
6. Gamelin E, Boisdron-Celle M, Guerin-Meyer V, et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 1999;17:1105-1110.
7. Bocci G, Danesi R, Di Paolo A, et al. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. Clin Cancer Res. 2000;6:3032-3037.
8. Di Paolo A, Danesi R, Vannozzi F, et al. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer. Clin Pharmacol Ther. 2002;72:627-637.
9. Gamelin E, Boisdron-Celle M, Delva R, et al. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol. 1998;16:1470-1478.
10. van Kuilenburg AB, De Abreu RA, van Gennip AH. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Ann Clin Biochem. 2003;40:41-45.
11. Baba H, Teramoto K, Kawamura T, et al. Dihydropyrimidine dehydrogenase and thymidylate synthase activities in hepatocellular carcinomas and in diseased livers. Cancer Chemother Pharmacol. 2003;52:469-476.
12. Diasio RB. Current status of oral chemotherapy for colorectal cancer. Oncology. 2001;15(Suppl 5):16-20.
13. Adjei AA, Reid JM, Diasio RB, et al. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. J Clin Oncol. 2002;20:1683-1691.
14. Etienne MC, Lagrange JL, Dassonville O, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol. 1994; 12:2248-2253.
15. Milano G, Etienne MC, Pierrefite V, et al. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer. 1999;79:627-630.
16. Ridge SA, Sludden J, Wei X, et al. Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. Br J Cancer. 1998; 77:497-500.
17. Takimoto CH, Lu ZH, Zhang R, et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res. 1996;2:477-481.
18. Bocci G, Danesi R, Allegrini G, et al. Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report. Eur J Clin Pharmacol. 2002;58:593-595.
19. van Kuilenburg AB, Baars JW, Meinsma R, et al. Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene. Ann Oncol. 2003;14:341-342.
20. Ezzeldin H, Johnson MR, Okamoto Y, et al. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clin Cancer Res. 2003;9:3021-3028.
21. Ridge SA, Sludden J, Wei X, et al. Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. Br J Cancer. 1998; 77:497-500.
22. Ackland SP, Garg MB, Dunstan RH. Simultaneous determination of dihydrofluorouracil and 5-fluorouracil in plasma by high-performance liquid chromatography. Anal Biochem. 1997;246:79-85.
23. Déporte-Féty R, Picot M, Amiand M, et al. High-performance liquid Chromatographic assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes: application to measurement of dihydropyrimidine dehydrogenase activity. J Chromatogr B. 2001;762:203-209.
24. Yokota H, Fernandez-Salguero P, Furuya H, et al. cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria. J Biol Chem. 1994;269:23192-23196.
25. Nakamura A, Kikuchi K, Ohishi T, et al. Assay method for uracil, dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil by high-performance liquid chromatography. Gan To Kagaku Ryoho. 2004;31:381-386.
26. Garg MB, Sevester JC, Sakoff JA, et al. Simple liquid Chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;774:223-230.
27. Rowland M, Tozer TN. Clinical Pharmacokinetics. Concepts and Applications, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 1999.
28. Wilke HJ, Van Cutsem E. Current treatments and future perspectives in colorectal and gastric cancer. Ann Oncol. 2003;14(Suppl 2):49-55.